FY2019 · ended Dec 31, 2019 · Revenue $0 · Filed Mar 10, 2022
Achieve Life Sciences, Inc. (ACHV) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. Free cash flow was -$49.5 million. As of Jun 30, 2026 it held $187.3 million in cash and investments and $41,000 in total debt.
Revenue
$0
Net income
$-54.65M
-37.2% vs prior year
Operating cash flow (TTM)
$-47.02M
-18.4% vs year-ago TTM
Free cash flow
$-49.47M
-101.9% vs prior year
EPS
$-1.25
-0.8% vs prior year
Dividend per share
None
Shares outstanding
102.66M
+92.8% vs prior year
Net cash
$187.26M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- ACHV (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 949858
- Former names
- ONCOGENEX PHARMACEUTICALS, INC. (until Jul 31, 2017); SONUS PHARMACEUTICALS INC (until Aug 7, 2008)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Net income | -$54.6M | -$39.8M | -$29.8M | -$42.4M | -$33.2M |
| Diluted EPS | -$1.25 | -$1.24 | -$1.50 | -$4.00 | — |
| Operating cash flow | -$49.5M | -$29.8M | -$24.5M | -$37.6M | -$29.4M |
| Free cash flow | -$49.5M | — | -$24.5M | — | — |
| Total assets | $41.8M | $38.6M | $19.4M | $30.0M | $47.5M |
| Total liabilities | $20.3M | $17.7M | $20.8M | $21.7M | $19.5M |
| Stockholders' equity | $21.5M | $20.9M | -$1.4M | $8.3M | $28.0M |
| Cash and investments | $36.4M | $34.4M | $15.5M | $24.8M | $43.0M |
| Total debt | $66,000 | $121,000 | $69,000 | $127,000 | $73,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Other events
|
Aug 14, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jul 6, 2026 | Jul 2, 2026 |
| ARS | Annual report to shareholders | Jun 8, 2026 | Dec 31, 2025 |
All 1000 Achieve Life Sciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.